Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of pGA2/JS7 DNA and MVA/HIV62, or of MVA/HIV62 alone, in healthy, HIV uninfected vaccinia-naive adult participants

Next Previous
Trial Profile

A phase 2a clinical trial to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of pGA2/JS7 DNA and MVA/HIV62, or of MVA/HIV62 alone, in healthy, HIV uninfected vaccinia-naive adult participants

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GOVX-B11 (Primary) ; MVA-HIV62 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms HVTN 205

Most Recent Events

  • 20 Mar 2015 A follow-up study to this trial, in which patients are given a protein boost to evaluate their immune responses, is expected to be initiated in late 2015, according to a GeoVax media release.
  • 09 Oct 2013 Additional results have been presented at the 2013 AIDS Vaccine Meeting according to a GeoVax Labs media release. Results were also reported in the media release.
  • 01 Oct 2012 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top